NASDAQ$TVTX

Travere Therapeutics Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Travere reported financial results and organizational progress for Q3 2021.

Travere Therapeutics reported net product sales of $54.2 million for the third quarter of 2021. The company is on track for an NDA submission for accelerated approval in the first quarter of next year.

  • Positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy were reported.
  • NDA submission of sparsentan in IgA nephropathy for accelerated approval under Subpart H is expected in the first quarter of 2022.
  • Accelerated approval submission of sparsentan in FSGS is planned for mid-2022, pending additional supportive eGFR data from the ongoing DUPLEX Study.
  • A joint collaboration with Vifor Pharma will commercialize sparsentan in Europe; a combined IgA nephropathy and FSGS MAA submission for sparsentan in Europe is expected mid-2022.

Headline financials

Total Revenue

$68.2M

Previous: $51.1M+33.4%
EPS (adj)

-$0.13

Previous: -$0.11-18.2%
Capital Expenditures

-$4.95M

Previous: -$2.93M-69.1%
Free Cash Flow

-$40.6M

Previous: -$25.5M-59.3%
Net Income

-$35.6M

Previous: -$22.5M-58.1%
Operating Income

-$31.7M

Previous: -$19.4M-63.2%
Gross Profit

$66.6M

Previous: $50M+33.4%
Cash & Equivalents

$150M

Previous: $200M-25.0%
Total Assets

$775M

Previous: $692M+12.0%
Stock-Based Comp

$6.76M

Previous: $5.14M+31.5%

Revenue & EPS history

Travere · Revenue · Quarterly

$68.2M

Q3 2021+33.4%vs Q3 2020
Beat estimate in 8 of 16 quarters(50%)
ActualEstimate

Revenue by segment

Travere · $33.9M total across 2 segments · Q3 2023

  • Tiopronin products
    $25.9M+2.0%
  • FILSPARI
    $8.04M

Forward guidance

Travere expects to continue strong execution through the balance of 2021, and to build upon the strength of their existing commercial organization to prepare for multiple potential launches of sparsentan, if approved.

Tailwinds

  • NDA submission for accelerated approval in the first quarter of next year.
  • Potential NDA submission for accelerated approval of sparsentan for FSGS.
  • Combined IgA nephropathy and FSGS MAA submission for conditional marketing authorization in Europe.
  • Preliminary eGFR data available at the time of the interim analysis are indicative of a potential clinically meaningful treatment effect after two years of treatment.
  • The PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance.

Headwinds

  • The company faces risks associated with market acceptance of its commercial products including efficacy, safety, price, reimbursement and benefit over competing therapies.
  • The company faces the risk that the Phase 3 DUPLEX Study of sparsentan in FSGS will not demonstrate that sparsentan is safe or effective or serve as a basis for accelerated approval of sparsentan as planned.
  • The company faces the risk that the Phase 3 PROTECT Study of sparsentan in IgAN will not demonstrate that sparsentan is safe or effective or serve as the basis for accelerated approval of sparsentan as planned.
  • There is no guarantee that the FDA will grant accelerated approval of sparsentan for IgAN or FSGS or that sparsentan will be approved at all.
  • The Company faces additional risks associated with the potential impacts the COVID-19 pandemic may have on its business

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.6%

Avg return

Earnings day

-1.3%

Avg return

5 days after

-0.3%

Avg return

30 days after

49%

25 / 51 earnings

Positive

+16.6%

Q3 2025

Best reaction

-16.7%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.8%-5.1%+2.8%
Q4 2025+3.1%+0.1%-8.4%
Q3 2025+16.6%+13.7%+19.4%
Q1 2025+1.6%-2.6%-27.6%
Q4 2024-6.8%-10.8%-12.9%
Q3 2024-1.1%-0.0%+5.9%
Q2 2024-5.7%-6.7%-0.7%
Q1 2024+7.8%+0.6%+25.1%
Q4 2023-0.6%+0.4%-9.2%
Q3 2023-4.7%-16.0%+30.3%
Q2 2023-6.6%-6.7%-10.5%
Q1 2023+5.6%+4.2%+19.7%
Q4 2022+6.9%+6.2%+0.0%
Q3 2022+3.1%+0.5%-12.4%
Q2 2022+16.0%+16.2%+13.5%
Q1 2022-14.2%-13.2%-6.4%
Q4 2021+2.9%+2.1%-3.3%
Q3 2021+10.0%+15.1%+10.8%
Q2 2021-2.4%+0.5%+52.7%
Q1 2021-16.6%-17.4%-41.2%
Q4 2020-5.3%-12.4%-19.0%
Q3 2020+1.6%+11.4%+18.1%
Q2 2020-1.6%-4.1%-4.3%
Q1 2020+7.6%+0.8%-0.9%
Q4 2019-16.7%-10.3%-21.4%
Q3 2019+4.4%+8.0%+20.7%
Q2 2019-11.4%-2.7%-34.0%
Q1 2019-7.9%-5.5%-2.7%
Q4 2018+5.6%+4.3%+7.7%
Q3 2018+0.6%+1.2%-4.4%
Q2 2018-4.4%-4.2%+2.4%
Q1 2018-5.2%-5.7%+11.6%
Q4 2017+5.4%+5.2%-5.8%
Q3 2017-13.4%-16.3%-17.1%
Q2 2017-0.1%+7.6%+15.8%
Q1 2017-4.4%-6.5%-7.1%
Q4 2016+1.5%-0.6%-13.2%
Q3 2016-4.3%-1.2%+8.5%
Q2 2016+1.4%-1.9%-13.6%
Q1 2016+5.2%
Q4 2015-2.8%
Q3 2015-10.0%
Q2 2015+13.0%
Q1 2015+5.8%
Q4 2014+9.5%
Q3 2014-14.4%
Q2 2014-6.2%
Q1 2014+4.9%
Q4 2013+8.4%
Q3 2013-5.8%
Q2 2012-9.9%
Q3 2012
Q1 2012
Q4 2012
Q3 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro